August 27, 2026 | Intelligent Congress, Pharma, healthcare
This guidebook explores how Intelligent Congress helps pharma teams create more coordinated, measurable, and impactful congress strategies.

Congresses remain one of the most influential moments in the HCP journey, but many organizations still struggle to connect strategy, engagement, and measurement across the congress lifecycle. As a result, valuable opportunities to maximize impact are often missed.
Our latest Intelligent Congress guidebook introduces a practical four-step framework to help pharma teams transform congresses from isolated activities into connected, measurable experiences. Covering strategic alignment, integrated measurement, seamless HCP engagement, and streamlined execution, it provides a roadmap for creating more coordinated congress strategies that deliver greater business impact.
Download here.
This content was provided by Inizio
Latest Content from Inizio
Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.
Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding.
Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding
Oncology is arguably the most exciting area of medicine in which to be working today. Biomarkers and companion diagnostics offer incredibly valuable predictive power, which is of benefit to payers,…
Pegasus, the UK’s leading independent health communications consultancy, added three awards to its 2014 portfolio at last weekend’s AMEC International Summit 2014 in Amsterdam
Brighton consultancy adds top honour to its award wins
Brighton-based independent healthcare specialist looks to add award to growing list of accolades
Top UK Healthcare Communications Consultancy Moves to Brighton
A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation…
Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.
